Last $14.47 USD
Change Today -0.1005 / -0.69%
Volume 8.0K
ALPMY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc-unsp adr (ALPMY) Snapshot

Open
$14.41
Previous Close
$14.57
Day High
$14.49
Day Low
$14.37
52 Week High
08/18/14 - $14.64
52 Week Low
10/9/13 - $9.74
Market Cap
33.1B
Average Volume 10 Days
18.1K
EPS TTM
--
Shares Outstanding
2.3B
EX-Date
03/26/14
P/E TM
--
Dividend
$0.27
Dividend Yield
1.82%
Current Stock Chart for ASTELLAS PHARMA INC-UNSP ADR (ALPMY)

Related News

No related news articles were found.

astellas pharma inc-unsp adr (ALPMY) Related Businessweek News

View More BusinessWeek News

astellas pharma inc-unsp adr (ALPMY) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The company’s products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, it offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. It has a strategic alliance with Amgen Inc.; a collaborative research agreement with Immuno-Biological Laboratories Co., Ltd.; a compound library sharing partnership with Daiichi Sankyo Company, Limited; and a strategic partnership with ClearPath Development Company. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc-unsp adr (ALPMY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

astellas pharma inc-unsp adr (ALPMY) Key Developments

Cancer Research UK and Cancer Research Technology Join Forces with Astellas Pharma, Inc. on Autophagy to Find New Cancer Treatments

Cancer Research UK and Cancer Research Technology are to join forces with Astellas Pharma Inc. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer. As part of a new collaboration, Cancer Research UK, CRT and Astellas will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer. Certain pancreatic cancers are dependent on autophagy, the process of consuming own cellular parts for energy, in order to grow. Blocking this pathway may help stop some pancreatic cancers. Under the terms of the deal, the first stage aims to identify and then validate the best possible drug targets to block the autophagy pathway in pancreatic cancer cells. This research will be carried out by Professor Kevin Ryan at the Cancer Research UK Beatson Institute and Dr. Sharon Tooze at the Cancer Research UK London Research Institute. Astellas has an exclusive licence to progress the most promising candidates through further drug discovery and development, subject to certain milestone and royalty payments to CRT. New treatments are desperately needed for pancreatic cancer -- one of the deadliest forms of cancer. Every year 8,800 people are diagnosed with the disease in the UK but survival rates remain very low, with only 3% of people diagnosed with pancreatic cancer surviving their disease for five years or more after their diagnosis.

Astellas Pharma, Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Earnings Guidance for the Full Year Ending March 31, 2015

Astellas Pharma, Inc. reported consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company's sales were JPY 295,157 million compared to JPY 269,505 million a year ago. Operating profit was JPY 50,565 million compared to JPY 26,410 million a year ago. Profit before tax was JPY 50,278 million compared to JPY 26,380 million a year ago. Profit was JPY 35,861 million or JPY 16.13 per diluted share compared to JPY 19,827 million or JPY 8.78 per diluted share a year ago. Profit attributable to owners of the parent was JPY 35,861 million compared to JPY 19,827 million a year ago. Net cash flows from operating activities was JPY 60,653 million compared to JPY 45,669 million a year ago. Purchase of property, plant and equipment was JPY 5,348 million compared to JPY 6,476 million a year ago. Purchase of intangible assets was JPY 11,519 million compared to JPY 7,504 million a year ago. Core operating profit was JPY 66 billion compared to JPY 44.5 billion a year ago. Core profit before tax was JPY 66.8 billion compared to JPY 45.1 billion a year ago. Core profit was JPY 46.4 billion compared to JPY 31.8 billion a year ago. Core earnings per share was JPY 20.90 compared to JPY 14.07 a year ago. The company provided earnings guidance for the full year ending March 31, 2015. For the year, the company expects core sales of JPY 1,192 billion, core operating profit of JPY 208 billion, core profit of JPY 154 billion or JPY 69.65 per share.

Astellas Pharma, Inc., Q1 2015 Earnings Call, Aug 01, 2014

Astellas Pharma, Inc., Q1 2015 Earnings Call, Aug 01, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $14.47 USD -0.1005

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $75.25 USD +0.12
Becton Dickinson and Co $117.64 USD -0.58
CSL Ltd A$73.54 AUD +0.81
Takeda Pharmaceutical Co Ltd ¥4,729 JPY +42.50
Valeant Pharmaceuticals International Inc C$124.10 CAD -0.41
View Industry Companies
 

Industry Analysis

ALPMY

Industry Average

Valuation ALPMY Industry Range
Price/Earnings 30.9x
Price/Sales 2.8x
Price/Book 2.7x
Price/Cash Flow 23.3x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.